Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing?
Finn
Aloke V
AV
Nakazawa
Gaku
G
Kolodgie
Frank D
FD
Virmani
Renu
R
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D000818:Animals; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D003324:Coronary Artery Disease / Q000473:pathology / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D003331:Coronary Vessels / Q000473:pathology*; D054855:Drug-Eluting Stents; D006801:Humans; D006965:Hyperplasia; D017239:Paclitaxel / Q000008:administration & dosage; D011108:Polymers / Q000737:chemistry; D011474:Prosthesis Design; D018570:Risk Assessment; D020123:Sirolimus / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D017539:Tunica Intima / Q000473:pathology*
D002317:Cardiovascular Agents; D011108:Polymers; D017239:Paclitaxel; D020123:Sirolimus